Skip to main content
Sarbjit Saini, MD, Allergy & Immunology, Baltimore, MD, Johns Hopkins Hospital

SarbjitSinghSainiMD

Allergy & Immunology Baltimore, MD

Asthma & Allergic Conditions

Professor of Medicine, Johns Hopkins University School of Medicine Director, Allergy and Immunology Fellowship Program

Dr. Saini is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Saini's full profile

Already have an account?

  • Office

    5501 Hopkins Bayview Circle
    Asthma and Allergy Center
    Baltimore, MD 21224
    Phone+1 410-550-2300
    Fax+1 410-550-3256
  • Is this information wrong?

Summary

  • Dr. Sarbjit Saini is an allergist/immunologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 26 years.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Allergy and Immunology, 1994 - 1997
  • University of Michigan Health System
    University of Michigan Health SystemResidency, Internal Medicine, 1991 - 1994
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1991

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2020 - Present
  • MD State Medical License
    MD State Medical License 1995 - 2025
  • MI State Medical License
    MI State Medical License 1993 - 1997
  • American Board of Allergy and Immunology Allergy & Immunology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Novel BTK Inhibitor for Chronic Hives Wins in Phase III Trial
    Novel BTK Inhibitor for Chronic Hives Wins in Phase III TrialNovember 16th, 2023

Hospital Affiliations